The first piece of Crystal River-3’s reactor pressure vessel is lifted from the reactor cavity. (Photo: Orano)

The cutting and conditioning of the reactor pressure vessel (RPV) and internals belonging to the pressurized water reactor at the Crystal River-3 nuclear power plant in Florida has been completed, the Orano Group has announced. Finished in under two years, removal of the RPV marks the conclusion of the plant’s dismantling and spent fuel management project, which began in 2021.

Crystal River-3 is being decommissioned by Advanced Decommissioning Partners (ADP), a joint venture of Orano and NorthStar Group Services. Duke Energy transferred the licenses for Crystal River-3 to ADP in October 2020 for accelerated decommissioning.

Optimized process: Orano’s Dismantling and Services teams carried out the cutting and conditioning of the reactor vessel and primary circuit components using a patented segmentation process called “optimized segmentation,” according to the company.

GE Hitachi Nuclear Energy announced May 9 that it intends to transfer ownership of the 1,600-acre GEH Vallecitos Nuclear Center to NorthStar Group Services for nuclear decontamination, decommissioning, and environmental site restoration.

The rapid changes in the nuclear energy industry over the last decade, driven in part by fluctuating energy market prices and an aging fleet of reactors, have led to the closure of multiple reactors in the United States and other countries. These closures have increased the need for larger and more efficient ways to manage low-level radioactive waste processing and transport capacities. The safe transport of radioactive material is a key component of the overall nuclear industry reliability. Though sometimes perceived as a bottleneck and costly, it is necessary to send waste material to disposal.

Nuclear medicine company NorthStar Medical Radioisotopes announced that it has successfully produced molybdenum-99 at its recently completed accelerator production facility at its Beloit, Wis., campus. According to NorthStar, the event marks a major milestone in advancing the company’s proprietary electron accelerator technology for the non-uranium–based production of the critical medical radioisotope.

NorthStar Medical Radioisotopes has completed construction and all equipment installation at its new facility in Beloit, Wis., to produce the medical radioisotope molybdenum-99 without the use of high-enriched uranium, the Department of Energy’s National Nuclear Security Administration announced last week.

NorthStar Medical Technologies of Beloit, Wis., will receive $37 million under two cooperative agreements with the National Nuclear Security Administration for the production of molybdenum-99 without the use of high-enriched uranium. Considered a critical medical radioisotope, Mo-99 is used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.

The Nuclear Regulatory Commission is set to allow about 2 million gallons of low-level radioactive wastewater from the Vermont Yankee nuclear power plant, currently undergoing decommissioning, to be disposed of at an Idaho waste facility. As published in the May 7 Federal Register, the NRC has issued an environmental assessment and finding of no significant impact for a request by NorthStar Nuclear Decommissioning to dispose of the wastewater at US Ecology Idaho’s waste facility near Grand View.

Completing a 5,700-mile journey from Belgium, two 24-ton particle accelerators were delivered to NorthStar Medical Radioisotopes’ facility in Beloit, Wis., on April 22, the Wisconsin State Journal reported. Photos and a video of the accelerators being received at the facility are included in the report.